Macaulay Onuigbo, MD
Nephrology · Burlington, VTNPI 1699731893
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,206 of the $24,844 with a category attached, or 69.3%. 5 manufacturers reported payments, led by Travere Therapeutics, Inc. at 52.4% of the total.
Across 40 payments — averaging $621.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$13K
- AstraZeneca$8K
- Calliditas Therapeutics US Inc.$3K
- Bayer$1K
- Viiv Healthcare Company$211
What the payments were for
- Consulting fees$17,20669%
- Speaking & faculty fees$1,3525%
- Travel & lodging$4,61119%
- Food & beverage$1,6767%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 27 | $13,030 |
| AstraZeneca | 9 | $7,590 |
| Calliditas Therapeutics US Inc. | 1 | $2,661 |
| Bayer | 1 | $1,352 |
| Viiv Healthcare Company | 2 | $211 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few nephrology providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProsolParenteral Amino Acid 20% No.1 | 52 | $9,411 |
| Sevelamer Carbonate | 56 | $5,195 |
| Calcium Acetate | 29 | $1,246 |
| Torsemide | 39 | $1,123 |
| Labetalol Hcl | 15 | $755 |
| Midodrine Hcl | 14 | $687 |
| Nifedipine ErNifedipine | 17 | $604 |
| Spironolactone | 14 | $180 |
| Hydralazine Hcl | 11 | $174 |
| Potassium Chloride | 12 | $142 |
| Amlodipine Besylate | 17 | $130 |
| Hydrochlorothiazide | 15 | $90 |
| Prednisone | 20 | $44 |
| Metoprolol Succinate | 12 | $40 |
| Famotidine | 13 | $15 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Burlington
- Nuria Pastor SolerBurlington$15K
- Kenneth HallowsBurlington$14K
- Richard SolomonBurlington$10K
- Abhishek KumarBurlington$509
- Silviana MarineciBurlington$249
- Virginia HoodBurlington$0
- Jeffrey RimmerBurlington$0
- Alison FitzgeraldBurlington$0
- Robert RobeyWhite River Jct$483
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.